Bristol-Myers Squibb Company
A biopharmaceutical company that discovers and sells medicines for cancer, heart, immune, and brain conditions, with well-known brands like the immunotherapy Opdivo, the blood thinner Eliquis, and the cell therapy Breyanzi. It was formed in 1989 when two old American drugmakers merged: Bristol-Myers, started in 1887 by two college friends who bought a struggling New York firm, and Squibb, founded in 1858 by a doctor who supplied the Union Army during the Civil War. A fun early hit for the Bristol-Myers side was Sal Hepatica, a mineral-salt laxative meant to mimic natural mineral waters.
Granted 3.70M · Sold 1.73M
Granted 1.83M · Bought 15.0K · Sold 1.25M
Granted 171.3K
Granted 1.04M · Sold 218.6K
Granted 1.58M · Sold 606.5K
Granted 466.2K · Sold 451.0K
Granted 1.96M · Sold 720.3K
Granted 85.1K
Granted 766.3K · Sold 396.0K
Granted 384.0K · Sold 228.7K
Granted 393.7K · Bought 7.1K · Sold 29.5K
Granted 138.1K
Granted 494.8K · Sold 21.5K
Granted 348.1K · Sold 122.4K
Granted 587.8K · Sold 436.6K
Granted 768.2K · Sold 319.6K
Granted 41.1K
Granted 20.0K
Granted 263.4K · Sold 168.2K
Granted 14.0K
Granted 172.2K · Bought 7.9K
Granted 3.21M · Bought 100.9K · Sold 2.11M
Granted 20.8K
Granted 45.2K · Sold 10.9K
Granted 13.2K
Granted 131.4K
Granted 12.6K · Sold 4.0K
Granted 202.6K · Sold 109.5K
Granted 94.6K
Granted 48.4K
Granted 714.1K · Sold 534.4K
Granted 25.7K
Granted 348.5K · Sold 225.1K
Granted 58.2K
Granted 9.1K
Granted 4.2K
Granted 4.2K
Bought 35.5K
Granted 50.2K · Sold 28.5K
Granted 52.7K
Granted 26.9K · Sold 3.2K
Granted 38.5K · Sold 732
Granted 34.1K
Granted 268.2K · Sold 139.4K
Granted 164.0K · Sold 120.9K
Granted 4.2K
Granted 131.1K · Sold 93.7K
Granted 67.9K
Granted 26.7K · Sold 97.39
Bought 25.0K
Granted 68.3K
Granted 44.4K · Sold 5.3K
Granted 3.3K · Bought 18.7K
Granted 5.3K
Granted 28.6K
Granted 18.9K · Sold 1.2K
Granted 35.9K · Sold 9.6K
Granted 23.9K · Sold 378
Granted 14.9K · Sold 11.4K
Granted 27.7K
Granted 14.3K · Bought 88
Bought 11.0K
Granted 17.7K · Sold 6.4K
Granted 14.5K · Sold 14.5K
Granted 6.1K
Granted 11.3K
Granted 19.1K
Granted 20.0K
Granted 5.4K
Bought 5.0K · Sold 1.6K
Sold 2.7K
Granted 53.1K · Sold 14.5K
Granted 1.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Andreotti LambertoDirector · 202 transactions | — | 1.18Mas of Apr 2017 | 3.70M | — | 1.73M |
| Sigal ElliotEVP, CSO & President R&D, Director · 112 transactions | — | 1.03Mas of Jun 2013 | 1.83M | 15.0K | 1.25M |
| Dolan Peter RFormer CEO, Director · 7 transactions | — | 606.9Kas of Sep 2006 | 171.3K | — | — |
| Bancroft Charles AEVP, Head of Integration · 183 transactions | — | 529.8Kas of Mar 2020 | 1.04M | — | 218.6K |
| Leung SandraEVP, General Counsel · 252 transactions | — | 455.5Kas of Mar 2025 | 1.58M | — | 606.5K |
| Celentano John ESVP HR Public Affairs & Philan · 74 transactions | — | 407.4Kas of Mar 2012 | 466.2K | — | 451.0K |
| Caforio GiovanniExecutive Chair of the Board, Director · 235 transactions | — | 386.8Kas of Mar 2024 | 1.96M | — | 720.3K |
| Bodnar Andrew GSVP, Strat & Med & Ext Affairs · 7 transactions | — | 323.5Kas of Sep 2006 | 85.1K | — | — |
| Cuss Francis MEVP & CSO · 116 transactions | — | 302.2Kas of Mar 2017 | 766.3K | — | 396.0K |
| von Autenried PaulEVP, Chief Information Officer · 163 transactions | — | 292.9Kas of Nov 2021 | 384.0K | — | 228.7K |
| Boerner Christopher S.Chief Executive Officer, Director · 131 transactions | — | 261.7K | 393.7K | 7.1K | 29.5K |
| McGoldrick John LExecutive VP · 6 transactions | — | 224.0Kas of Mar 2006 | 138.1K | — | — |
| Hooper Anthony CSVP ComOps Pres USJap Int · 39 transactions | — | 208.4Kas of May 2011 | 494.8K | — | 21.5K |
| Carlo de NotaristefaniPres Tech Ops & Supp Fnctns · 39 transactions | — | 198.6Kas of Jun 2011 | 348.1K | — | 122.4K |
| Cazala Beatrice JEVP Commercial Operations · 67 transactions | — | 177.1Kas of Jun 2013 | 587.8K | — | 436.6K |
| Elkins David VEVP, Chief Financial Officer · 87 transactions | — | 159.5K | 768.2K | — | 319.6K |
| Bonfield Andrew R JEVP & CFO · 12 transactions | — | 144.5Kas of Mar 2008 | 41.1K | — | — |
| Willard Richard KSVP & General Counsel · 1 transaction | — | 120.0Kas of Mar 2006 | 20.0K | — | — |
| Daniels BrianSVP Global Dev & Med Affairs · 79 transactions | — | 94.4Kas of Jul 2014 | 263.4K | — | 168.2K |
| Dixon Wendy LCMO & Pres, Global Marketing · 4 transactions | — | 88.5Kas of May 2006 | 14.0K | — | — |
| Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. · 53 transactions | — | 83.5Kas of Apr 2025 | 172.2K | 7.9K | — |
| Cornelius James MDirector · 194 transactions | — | 79.9Kas of Mar 2015 | 3.21M | 100.9K | 2.11M |
| Bear Stephen ESVP, Human Resources · 12 transactions | — | 73.8Kas of Mar 2008 | 20.8K | — | — |
| Zabor David LVP Strat Bus Initiatives · 10 transactions | — | 71.8Kas of Jul 2006 | 45.2K | — | 10.9K |
| Howson Tamar DSVP, Corp & Bus Development · 6 transactions | — | 71.5Kas of Dec 2006 | 13.2K | — | — |
| Judge Ann PowellSVP, Global Human Resources · 70 transactions | — | 65.7Kas of Mar 2019 | 131.4K | — | — |
| McBride Anthony ASVP Human Resources · 20 transactions | — | 64.2Kas of Mar 2010 | 12.6K | — | 4.0K |
| Elicker John EEVP, Investor Relations · 146 transactions | — | 62.8Kas of Mar 2020 | 202.6K | — | 109.5K |
| Gordon MurdoEVP, Chief Commercial Officer · 52 transactions | — | 50.2Kas of Aug 2018 | 94.6K | — | — |
| Ahmed NadimEVP and President, Hematology · 12 transactions | — | 48.5Kas of Jan 2021 | 48.4K | — | — |
| Vessey RupertEVP & President, Research · 97 transactions | — | 48.4Kas of May 2023 | 714.1K | — | 534.4K |
| Levin Jeremy MSVP Strat Transactions · 13 transactions | — | 48.4Kas of Oct 2011 | 25.7K | — | — |
| Caldarella Joseph CSVP & Controller · 155 transactions | — | 48.1Kas of Sep 2017 | 348.5K | — | 225.1K |
| Lenkowsky AdamEVP, Chief Commercial Officer · 38 transactions | — | 46.8K | 58.2K | — | — |
| Wolgemuth Richard LSVP, Global Reg Sciences · 3 transactions | — | 46.2Kas of Mar 2006 | 9.1K | — | — |
| Gerstner Louis V JrDirector · 1 transaction | — | 42.4Kas of Mar 2006 | 4.2K | — | — |
| Robinson James D IIIDirector · 1 transaction | — | 38.6Kas of Mar 2006 | 4.2K | — | — |
| Samuels Theodore R. IIDirector · 5 transactions | — | 38.1Kas of Nov 2023 | — | 35.5K | — |
| Nielsen AnneChief Compliance & Ethics Off · 61 transactions | — | 38.0Kas of Sep 2017 | 50.2K | — | 28.5K |
| Mily ElizabethEVP, Strategy & BD · 27 transactions | — | 35.9Kas of Apr 2023 | 52.7K | — | — |
| Zito Robert TSVP & Chief Comm Officer · 15 transactions | — | 35.5Kas of Mar 2010 | 26.9K | — | 3.2K |
| Plenge Robert MEVP, Chief Research Officer · 33 transactions | — | 34.8K | 38.5K | — | 732 |
| Haller Julia ADirector · 8 transactions | — | 34.1K | 34.1K | — | — |
| Schmukler Louis SEVP,Pres.,Glob.Prod. & Supply · 124 transactions | — | 32.0Kas of May 2021 | 268.2K | — | 139.4K |
| Moed Samuel JSVP, Strat Plan & Analysis · 57 transactions | — | 31.6Kas of Mar 2015 | 164.0K | — | 120.9K |
| Allen Robert EDirector · 1 transaction | — | 30.9Kas of Mar 2006 | 4.2K | — | — |
| Powell AnnEVP, Chief Human Resources · 66 transactions | — | 27.9Kas of Aug 2023 | 131.1K | — | 93.7K |
| Shanahan KarinEVP, Chief Supply Chain & Ops · 31 transactions | — | 27.3K | 67.9K | — | — |
| Hickey BenjaminPresident, RayzeBio Org. · 9 transactions | — | 25.6K | 26.7K | — | 97.39 |
| Huet Jean-MarcEVP & CFO · 1 transaction | — | 25.0Kas of Apr 2009 | — | 25.0K | — |
| Meyers Gregory ScottEVP, Chief Digital & Tech Off. · 31 transactions | — | 24.6K | 68.3K | — | — |
| Lynch Thomas J. Jr.EVP & Chief Scientific Officer · 15 transactions | — | 22.2Kas of Apr 2019 | 44.4K | — | 5.3K |
| Paliwal Dinesh CDirector · 3 transactions | — | 22.1Kas of Jun 2020 | 3.3K | 18.7K | — |
| Dwyer Edward MVice President & Treasurer · 1 transaction | — | 19.4Kas of Mar 2006 | 5.3K | — | — |
| Gallman CariEVP, General Counsel · 38 transactions | — | 17.0K | 28.6K | — | — |
| Holzer Phil MSVP and Controller · 32 transactions | — | 16.9K | 18.9K | — | 1.2K |
| Santiago Karen MurphySVP & Controller · 85 transactions | — | 16.7Kas of Mar 2022 | 35.9K | — | 9.6K |
| Short Bartie WendyEVP, Corporate Affairs · 17 transactions | — | 16.0K | 23.9K | — | 378 |
| Dubow AdamSVP,ChiefCompliance&EthicsOff. · 51 transactions | — | 15.7Kas of Aug 2021 | 14.9K | — | 11.4K |
| Blin EmmanuelSVP, Chief Strategy Officer · 32 transactions | — | 15.1Kas of Mar 2017 | 27.7K | — | — |
| Bonney Michael WDirector · 8 transactions | — | 14.5Kas of Jun 2021 | 14.3K | 88 | — |
| Bertolini Robert JDirector · 1 transaction | — | 11.4Kas of Jul 2019 | — | 11.0K | — |
| Eid JosephSVP,Head Glob. Medical Affairs · 28 transactions | — | 9.5Kas of Jun 2021 | 17.7K | — | 6.4K |
| Glimcher Laurie H M.D.Director · 7 transactions | — | 8.5Kas of Jan 2013 | 14.5K | — | 14.5K |
| Heller Frances KSVP, Business Development · 5 transactions | — | 7.3Kas of Mar 2014 | 6.1K | — | — |
| Biondi PaulSVP, Head of Strategy & BD · 20 transactions | — | 6.2Kas of Oct 2019 | 11.3K | — | — |
| Poole Ahn AmandaEVP, Chief People Officer · 30 transactions | — | 6.1K | 19.1K | — | — |
| Hoch LynellePresident, Cell Therapy Org. · 30 transactions | — | 5.9K | 20.0K | — | — |
| Weese MichelleEVP, Corporate Affairs · 7 transactions | — | 3.5Kas of Jul 2023 | 5.4K | — | — |
| Grobstein MichaelDirector · 3 transactions | — | 3.4Kas of Dec 2009 | — | 5.0K | 1.6K |
| Lacy Alan JDirector · 1 transaction | — | 2.3Kas of Dec 2009 | — | — | 2.7K |
| Campbell Lewis BDirector · 14 transactions | — | 2.1Kas of Mar 2016 | 53.1K | — | 14.5K |
| Greenlees SharonSVP & Controller · 5 transactions | — | 609as of May 2023 | 1.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -9.92M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.